Welcome to our dedicated page for Krystal Biotech news (Ticker: KRYS), a resource for investors and traders seeking the latest updates and insights on Krystal Biotech stock.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company headquartered in Pittsburgh, Pennsylvania, focused on genetic medicines for diseases with high unmet medical needs. Its news flow reflects the evolution of a gene therapy business built around VYJUVEK, the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for dystrophic epidermolysis bullosa, and a growing pipeline across respiratory, ophthalmology, dermatology, oncology, and aesthetics.
On this page, readers can follow KRYS news related to commercial performance and global launches of VYJUVEK, including label updates, reimbursement milestones, and market expansions in regions such as Europe and Japan. Company updates also cover strategic objectives for building a rare disease franchise, including plans to increase the number of marketed rare disease medicines and to reach more patients worldwide through direct launches and specialty distributor networks.
Investors and observers will find frequent clinical and regulatory news on Krystal Biotech’s pipeline programs. This includes interim data from studies such as CORAL‑1 for KB407 in cystic fibrosis, SERPENTINE‑1 for KB408 in alpha‑1 antitrypsin deficiency lung disease, IOLITE for KB803 in ocular complications of DEB, EMERALD‑1 for KB801 in neurotrophic keratitis, and oncology trials of KB707 in non‑small cell lung cancer. Updates often detail safety and molecular findings, study design progress, and interactions with regulators, such as FDA platform technology designation for the HSV‑1 vector used in KB801.
Krystal Biotech also regularly announces participation in major healthcare and investor conferences, quarterly financial results, and corporate guidance through press releases and SEC filings. This news page aggregates those disclosures so that users tracking KRYS stock can review earnings announcements, business updates, and key clinical milestones in one place.
Krystal Biotech, Inc. (Nasdaq: KRYS) has announced the pricing of an underwritten public offering of 2,275,000 shares at $55.00 each, with gross proceeds expected to be about $125.1 million. The offering is set to close around May 21, 2020, and includes a 30-day option for underwriters to purchase an additional 341,250 shares. Proceeds will be used for advancing clinical trials and developing a manufacturing facility. Leading firms managing the offering include Cowen, Evercore ISI, and others.
Krystal Biotech (Nasdaq: KRYS) has announced an underwritten public offering of its common stock, granting underwriters a 30-day option for an additional 15% of shares. The offering is subject to market conditions and lacks definitive terms. Proceeds will fund the Phase 3 trial of KB103, advance KB105 development, and support clinical efforts for multiple other compounds. The company seeks to establish a certified manufacturing facility for its products and cover working capital needs. This offering is part of a shelf registration effective since May 4, 2020.
Krystal Biotech announced interim results from a Phase 1/2 clinical trial for KB105, targeting autosomal recessive congenital ichthyosis (ARCI). The treatment was well tolerated in three adult patients, with no adverse events reported. Notably, KB105 showed detectable TGM-1 expression in treated areas, indicating functional activity and reduced disease phenotype reversion. A Phase 2 study in pediatric patients is expected to begin in late 2020, aiming to further validate effectiveness using a new severity score scale.